QNTM 6-K/A
Quantum Biopharma Ltd. (QNTM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-39152
QUANTUM BIOPHARMA LTD.
(Registrant)
1 Adelaide Street East, Suite 801
Toronto, Ontario M5C 2V9
(Address of Principal Executive Offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This Amendment No. 1 (this “Amendment No. 1”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission on April 2, 2026, Accession Number 0001171843-26-002207 (the “Initial Report”), is being furnished solely to incorporate Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264). Except as set forth herein, there are no other changes to the Initial Report.
1
DOCUMENTS INCORPORATED BY REFERENCE
Exhibit 99.1 included with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| QUANTUM BIOPHARMA LTD. | ||
| (Registrant) | ||
| Date: September 8, 2026 | By |
/s/ Donal Carroll |
| Donal Carroll | ||
| Chief Financial Officer | ||
3
EXHIBIT INDEX
|
Exhibit |
Description of Exhibit | |
| 99.1 | Press Release dated April 2, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on April 2, 2026, Accession No. 0001171843-26-002207) | |
4